The Relapse of Epithelial Ovarian Cancer Under 2-Year Post-Treatment Observation Based on VEGF-A and VEGFR-2 Expression
Abstract
Background: Epithelial ovarian cancer is one of the most formidable lethal malignancies, with a 5-year survival rate of approximately 35% for advanced-stage ovarian carcinoma and a 10-year follow-up rate of about 18%. Although several regimens have been evaluated for improvement, relapse remains an inevitable challenge. Recently, specific prognostic factors related to “cell behavior”, including cell proliferation activity such as angiogenesis VEGF (vascular endothelial growth factors) have been recognized. Therefore, this study aims to predict relapse of epithelial ovarian cancer within two years of follow-up based on the expression of vascular endothelial growth factor A (VEGF-A) and vascular endothelial growth factor receptor-2 (VEGFR-2) at the mRNA and protein levels.
Methods: This study was conducted at “Dharmais” Cancer Hospital (DCH) with a retrospective cohort design in patients with advanced epithelial ovarian cancer who received complete treatment. The role of angiogenesis factors on relapse in epithelial ovarian cancer in 2 years of observation was evaluated. Semiquantitative expression analysis of VEGF-A and VEGFR-2 (protein) was conducted through the immunohistochemical method using the avidin-biotinperoxidase complex (ABC) method. Meanwhile, the semiquantitative expression of VEGF-A and VEGF-R2 (mRNA level) was carried out using RT-PCR (Reverse Transcription- Polymerase Chain Reaction) - Zyber Green Bioline Kit - method, with specific primers.
Results: From 2008 to 2012, only 20 patients were tested for the role of VEGF-A and VEGFR-2 on the incidence of relapse within two years of observation. Among the 20 patients examined for VEGF-A and VEGFR-2 expression, 50% remained disease-free for 20 months, resulting in a cumulative disease-free survival probability of 48.1% for the patient. Those with positive VEGF-A expression at the mRNA level had a shorter median disease-free survival time (18 months), with a lower disease-free survival probability. Patients who showed positive VEGFR-2 expression (at the protein level) had a shorter median disease-free survival time, a lower cumulative probability of disease-free survival (DFS), and a greater risk of relapse (3 times) than patients who did not express (negative) VEGFR-2. In addition, the ROC-based analysis was also performed.
Conclusions: Expression of both VEGF-A and VEGFR-2 at mRNA and protein levels can be used as a predictor for relapse of epithelial ovarian cancer. This study showed that a positive VEGF-A expression at the mRNA level is associated with a twofold higher risk of relapse, while positive VEGF-R2 expression at the protein level is associated with a threefold shorter risk of relapse than negative expression.
Keywords
DOI: 10.33371/ijoc.v17i4.1053
Article Metrics
Abstract View: 598, 
PDF Download: 342
References
Viral K, Chithrathara K, Nair IR, et al. Long-term survival outcome of advanced epithelial ovarian cancer: A single institutional study. Indian Journal of Cancer. 2021;58(3):342-348.
Giornelli GH. Management of relapsed ovarian cancer: a review. Springerplus. 2016 Jul 28;5(1):1197.
Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194-200.
Pratt A, Parrera M, Campo JMD. Prognostic Role of CA 12 nadir in stage IV Epithelial Ovarian Cancer. J Clin Oncol. 2008;26(10):1771-2.
Inciura A, Simavicius A, Juozaityte E, et al. Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients. BMC Cancer. 2006;6:153.
Agarwal R, Kaye SB. Prognostic factors in ovarian cancer: how close are we to a complete picture? Ann Oncol. 2005 Jan;16(1):4-6.
Ramirez I, Chon HS, Apte SM. The role of surgery in the management of epithelial ovarian cancer. Cancer Control. 2011 Jan;18(1):22-30.
Langdon SP, Smyth JF. Growth factors and Ovarian Cancer. Endocrine-Related Cancer. 1998;5(4):283-291.
Clark TG, Stewart ME, Altman DG, et al. A prognostic model for ovarian cancer. Br J Cancer. 2001;85(7):944-952.
Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538-18543.
Pecorelli S, Pasinetti B, Tisi G, et al. Ovarian and fallopian tube cancer [Internet]. 2014 [cited 2023 Aug 17]. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/0471463736.tnmp34.pub2.
Bamberg ES, Perret CW. Angiogenesis in epithelial ovarian cancer. Mol Pathol. 2002;55(6):348-359.
O'Toole SA, Sheppard BL, Laios A, et al. Potential predictors of chemotherapy respons in Ovarian Cancer-- How do we define chemosensitivity. Gynecol Oncol. 2007;104(2):345-351.
van der Burg ME, van Lent M, Burse M, et al. The Effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Eng J Med. 1995;332(10):629-634.
Marzsalek A, Alran S, Scholl S, et al. Outcome in advanced ovarian cancer following an appropriate and comprehensive effort at upfront cytoreduction: A twenty-year experience in a single cancer institute. Int J Surg Oncol. 2010;214919:1-8.
Skirnizdottir I, Seidal T, Sorbe B. A new prognostic model comparing p53, EGFR and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem inaccurate surgical staging. Inj. J Gynecol Cancer. 2004;14(2);259-70.
Borre M, Nerstrom B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res. 2000;6(5):1882-1890.
Manders P, Beex LVAM, Tjan-Heijnen VC, et al. The prognosis value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer. 2002;87(7):772-778.
Galizia G, Lieto E, Ferraraccio F, et al. Determination of molecular marker expression can predict clinical outcome in colon carcinoma. Clin Cancer Res. 2004;10(10); 3490-3499.
Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group. J Clin Oncol. 2006;24(6):4301-4308.
Yamamoto S, Konishi I, Mandai M, et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997;76(9):1221-1227.
Shen GH, Ghazizadeh M, Kawanami O, et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000;83(2):196-203.
Duncan TJ, Al-Attar A, Rolland P, et al. Vascular Endothelial Growth Factor Expression on Ovarian Cancer: A model for targeted use of novel therapies. Clin Cancer Res. 2008;14(10):3030-3035.
Nishida N, Yano H, Komai K, et al. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer. 2004;101(6):1364-1374.
Klasa-Mazurkiewicz D, Jarzab M, Milczek T, et al. Clinical Significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients. Pol J Pathol. 2011;1:31-40.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Email this article 
